1. Home
  2. News
  3. Recce Pharmaceuticals Ltd.
  4. Murdoch Childrens Research Institute, R435 Against H.Pylori
More Recce Pharmaceuticals Ltd. news
Recce Pharmaceuticals Ltd.ASX: RCE

Murdoch Childrens Research Institute, R435 Against H.Pylori

Sep 30, 2020 at 12:47 AM EDT · Issued by Recce Pharmaceuticals Ltd.

Filed with ASX · Sep 30, 2020 at 12:47 AM EDT · 3 pages · English

On 6ix: 6ix.com/news/murdoch-childrens-research-institute-r435-against-hpylori

Recce Pharmaceuticals Ltd. on 6ix

Story so far

  • Positive Oral Data on New RECCE 435 Against H. pyloriAug 4, 2020

Earlier from Recce Pharmaceuticals

  • Recce Completes Capital Raising of $27.95mSep 23, 2020
  • R327 Phase I Study - Australias CMAX Clinical FacilitySep 10, 2020
  • Positive & Concentration-Dependent Efficacy Against COVID-19Sep 8, 2020
  • Recce Pharmaceuticals Receives Innovation Connections GrantAug 31, 2020
  • Recce Pharmaceuticals Appoints James Graham as CEOAug 28, 2020

Later from Recce Pharmaceuticals

  • HREC Approval to Start Phase I/II Burns Wound StudyOct 15, 2020
  • Encouraging Results Against SARS-CoV-2 VirusNov 10, 2020
  • Anti-Viral Patent Granted in Japan for RECCE Anti-InfectivesNov 22, 2020
  • Recce Awarded AusIndustry Advanced Overseas (R&D) FindingNov 25, 2020
  • RCE Awarded AusIndustry Advanced Overseas Anti-Viral FindingDec 7, 2020
All Recce Pharmaceuticals news releases↗

Follow Recce Pharmaceuticals into a list and get an email when it puts out news.

Follow Recce Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer